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Abstracts / Osteoarthritis and Cartilage 20 (2012) S54–S296S86estimate the predictive value of uCTX-II, ROC curve analysis was employed
and area under the curve (AUC) was evaluated. p<0.05 was considered
statistically signiﬁcant.
Results: In female subjects, uCTX-II values signiﬁcantly increased according
to the severity of knee OA (Fig.1A). In male subjects, OA G3,4 group had
signiﬁcantly higher uCTX-II values than G0,1 group or G2 group (Fig.1B).
ĂFig 1. Relationship between knee X-ray OA grades and uCTX-II levels in (A)
female and (B) male subjects. Each box represents the 25th/50th (median)
to 75th percentiles. The lines outside the box represent the 10th and 90 th
percentiles. *; P<0.05. **; P<0.01, ***; P<0.001.
The mean levels of uCTX-II in each quartile were 152, 236, 345, 554 ng/
mmol Cre in female and 121, 188, 269, 469 in male. Higher quartiles (Q3
and Q4) of uCTX-II level included higher numbers of OA (G2) subjects in
female but not signiﬁcant in male (Fig.2).
ĂFig. 2 Quartiles by uCTX-II levels and proportion of OA grades in (A) female
and (B) male. Each quartile has 65 and 69 subjects in female and mal-
e.Signiﬁcant difference was observed only in female (p<0.0001,Chi-square).
ROC curve analysis for discriminating G2 OA showed that AUC was 0.65
and 0.61 in female and male, respectively. If cut-off is 300 in female,
sensitivity and speciﬁcity are 60 and 65 %, respectively.
Conclusions: uCTX-II is more useful in female older than 60 years but
a modest biomarker of knee OA X-ray grade by the single measurement in
the cross-sectional study. OA changes of other joints (e.g. lumbar spon-
dylosis) may affect the level of uCTX-II. Further analysis of longitudinal
changes of uCTX-II and knee OA grade using the data of 2007 (5th) and
2010 surveys is in progress.
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Purpose: The purpose of this studywas to evaluate the performancemetrics
of a new C2C sandwich immunoassay (IB-C2C-HUSA), including reproduc-
ibility and linearity as well as variation due to physical activity or food
consumption, to inform biospecimen collection protocols in clinical trials.
Type II collagen is themost abundant collagen inarticular cartilage, providing
tensile strength, and is cleaved by collagenases, resulting in the creation of
a neoepitope at the C terminus of the 3/4 length fragment, detectable in
human body ﬂuids by the C2C competitive ELISA. Once this initial cleavage
has occurred, proteases create subsequent degradation products containing
the C-terminal neoepitope that are detectable in human urine.
Methods: Forty participants with knee OA (20 patients for each of two
cohorts) were admitted overnight for serial urine sampling to assess the
variation of OA-related biomarkers. Urine samples were obtained on theevening (6-8PM) of Day 1 (T3; n¼34), prior to rising (8AM) from bed (T0;
n¼34), 1 hr after rising (9AM) without food consumption (T1a; n¼20), 1-2
hr after rising (9-10AM) with food consumption (T1; n¼34), and at noon, 4
hr after rising (T2; n¼14). Urine C2C was measured using the new IB-C2C-
HUSAand valueswere corrected for creatinine concentrations and reported
as ng/mmol Cr. The linearity of the assay was determined by testing each
urine sample at neat, 1:2, and 1:4 dilutions. The percent recovery was
calculated as the adjusted concentration versus the adjusted concentration
of the previous dilution. The acceptance criteria for linearity are between
70-130%. To assess for variation due to activity and food consumption across
the cohorts, the biomarker concentrations at each time point for each
subject were normalized to the mean concentration of the four time points
for that individual. Results were analyzed using non-parametric Friedman's
testwith Dunn's post-hocmultiple comparison test. To compare the results
of the newly formatted assay to the original C2C assay, correlation analyses
of the IB-C2C-HUSA toC2C valuesmeasuredpreviously in the same samples
was performed. Statistical analyses were performed using GraphPad soft-
ware and a p-value <0.05 was considered signiﬁcant.
Results: C2C was measurable in all urine samples using the new IB-C2C-
HUSA and values from analysis of neat samples were used for 98.5 percent
of the determinations. For samples that had concentrations higher than
the highest standard (5000 pg/ml), a dilution factor of 1:2 was used to
determine the ﬁnal concentration. The standard curve was linear
(R2¼0.992) and the assay was linear from neat to 1:4 dilutions with amean
percent recovery of 126%. The mean concentrations +SD and range for the
IB-C2C-HUSA biomarker at each time point (pg/ml) were as follows: T0:
1244+1055 (249-5246);T1a: 1635+1205 (344-5771); T1: 1871+1032 (443-
4952); T2: 1074+ (239-3213); T3: 1043+814 (240-3845). Whereas C2C
concentrations, uncorrected for urine creatinine, varied greatly within
a day (Fig 1A), C2C concentrations corrected for creatinine demonstrated
no statistically signiﬁcant variation of the biomarker with either activity
(T1a) or with food consumption (T1) (Fig 1B), the two conditions most
likely to affect sampling in a clinical trial. A comparison of values obtained
from the original C2C and the IB-C2C-HUSA assay at each time point
revealed a signiﬁcant correlation between the original and new formats for
T1a (p¼0.001, r2¼0.46), T1(p¼0.04, r2¼0.12) , and T2 (p¼0.03, r2¼0.33).
Conclusions: The new IB-C2C-HUSA immunoassay is a highly reproducible
sandwich assay that yielded measurable type II collagen neoepitope frag-
ments in all 136 samples tested. Compared with the original C2C compet-
itive ELISA, this new sandwich ELISA did not show variation due to activity.
This makes it useful for the measurement of collagen degradation in OA
studies, and in particular, it would be appropriate for analyses of legacy
samples, obtained without regard to standardization of time of collection.
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